The primary objective of this 22 week study is to investigate the change in glycosylated hemoglobin (HbA1c) after receiving the new drug, as compared to those receiving a placebo.

The primary objective of this study is to evaluate the efficacy of a new drug compared with a placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe Chronic Lower Back Pain.

The primary objectives of this study are to evaluate the 12-week safety, antiviral activity and tolerability of this new Hep C drug when given in combination with PEG and RIBA as measured by extended rapid virologic response.